Guideline大集合

Systemic lupus erythematosus

• 2012 ACR guideline for LN
• 2023 EULAR guideline for SLE
• 2024 ACR guideline for LN
• 2025 EULAR guideline for LN
• 2025 TSOC for secondary hypogammaglobulinemia
• 2025 ACR guideline for SLE：guideline summary
• 2025 ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare SLE manifestations

Rheumatoid arthritis

• 2021 ACR guideline for RA
• 2022 EULAR guideline for RA
• 2025 TSOC for secondary hypogammaglobulinemia

Ankylosing spondylitis

• 2019 ACR/SAA/SPARTAN guideline for AS & nr-axSpA
• 2022 ASAS-EULAR guideline for axSpA
• 2024 Updating the 2019 ACR/SAA/SPART guideline for AS & nr-axSpA
• 2025 BSR guideline for axSpA

Antiphospholipid syndrome

• 2019 EULAR guideline for APS

Sjogren's syndrome

• 2016 ACR guideline for SjS
• 2019 EULAR guideline for SjS
• 2024 BSR guideline for SjS

Idiopathic inflammatory myopathies

• 2021 ACR guideline for refractory IIM
• 2022 BSR guideline for IIM

Systemic sclerosis

• 2023 EULAR guideline for SSc
• 2024 BSR guideline for SSc

Psoriatic arthritis

• 2021 GRAPPA guideline for PsO and PsA
• 2024 EULAR guideline for PsA

Granulomatosis with polyangiitis

• 2022 EULAR guideline for AAV

Microscopic polyangiitis

• 2022 EULAR guideline for AAV

Eosinophilic granulomatosis with polyangiitis

• 2022 EULAR guideline for AAV

Polyarteritis nodosa

• 2021 ACR guideline for PAN

Giant cell arteritis

• 2018 EULAR guideline for large vessel vasculitis
• 2021 ACR guideline for large vessel vasculitis

Takayasu's arteritis

• 2018 EULAR guideline for large vessel vasculitis
• 2021 ACR guideline for large vessel vasculitis

Behcet's disease

• 2018 ACR guideline for BD
• 2018 EULAR guideline for BD

Fibromyalgia

• 2017 EULAR revised recommendation for the management of FM
• 2021纖維肌痛症台灣臨床處置指引